The EU joint HTA procedure: a gate or barrier for access?
Pharmaceutical Technology
DECEMBER 22, 2022
The new joint procedure will launch in Q1 2025 for oncology medicines and other advanced therapy medicinal products and extend to orphan drugs in 2028. However, he did point out that the joint assessment could be a useful way of narrowing down typically broad EMA label content to specific patient populations.
Let's personalize your content